<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546896</url>
  </required_header>
  <id_info>
    <org_study_id>bsp2010</org_study_id>
    <nct_id>NCT01546896</nct_id>
  </id_info>
  <brief_title>Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aims to investigate the efficacy and safety of buspirone in treating
      generalized anxiety disorder with depressive symptoms and to evaluate its neuroprotective
      effects using magnetic resonance imaging.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in depressive symptom scores at 8 weeks</measure>
    <time_frame>baseline and at 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in depressive symptom scores at 4 weeks</measure>
    <time_frame>baseline and at 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in depressive symptom scores at 1 week</measure>
    <time_frame>baseline and at 1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in anxiety symptom scores at 8 weeks</measure>
    <time_frame>baseline and at 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in anxiety symptom scores at 4 weeks</measure>
    <time_frame>baseline and at 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in anxiety symptom scores at 1 week</measure>
    <time_frame>baseline and at 1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in brain structure, function, and biochemical metabolism, analyzed using the computational approach</measure>
    <time_frame>baseline and at 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>buspirone+alprazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>alprazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buspirone+alprazolam</intervention_name>
    <description>day 1~7: buspirone 10mg/d + alprazolam 0.5mg / day 8~28: buspirone 20mg/d + alprazolam 0.5mg / day 29~56: buspirone 20~30mg/d + alprazolam 0.5mg</description>
    <arm_group_label>buspirone+alprazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alprazolam</intervention_name>
    <description>0.5mg/d</description>
    <arm_group_label>alprazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient Inclusion Criteria:

          -  Men and women aged between 20 and 65

          -  Diagnosis of generalized anxiety disorder as assessed by Structured Clinical Interview
             for DSM-IV (SCID-IV)

          -  Depressive symptom scores measured by Hamilton Depression Rating Scale at screening
             and baseline assessments: &gt;=8 and &lt;=16

        Healthy Control Subject Inclusion Criteria

          -  Healthy men and women aged between 20 and 65

        Exclusion Criteria:

          -  Presence of any major physical or neurological illness (e.g.， head trauma, epilepsy，
             seizure， stroke， cerebral tumor， multiple sclerosis，cerebrovascular disease，
             narrow-angle glaucoma， drug hypersensitivity， etc.)

          -  Drug abuse in past 3 months

          -  Contraindications to magnetic resonance imaging (e.g., pacemaker
             implantation，claustrophobia, etc.)

          -  Diagnosis of any Axis I disorder other than generalized anxiety disorder or presence
             of symptoms requiring hospitalization

          -  Major depressive episode during past 12 months

          -  Depressive symptom scores measured by Hamilton Depression Rating Scale: &gt;=17

          -  Women who are pregnant, breastfeeding, or planning pregnancy

          -  Contraindications to drugs used in the study (e.g., allergy, intolerance, etc.)

          -  Unstable medical illness or severe abnormality in laboratory test at screening
             assessment

          -  Use of psychoactive medications that may affect brain imaging findings

          -  Intelligence quotient below 80
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Kyoon Lyoo, MD, PhD, MMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>In Kyoon Lyoo, MD, PhD, MMS</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

